Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals
Convalescent plasma therapy, which involves administering plasma from recovered coronavirus disease 2019 (COVID-19) patients to infected individuals, is being explored as a potential treatment for severe cases of COVID-19. This study aims to evaluate the efficacy and safety of convalescent plasma th...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/11/2184 |
| _version_ | 1797458640211279872 |
|---|---|
| author | Mari Terada Sho Saito Satoshi Kutsuna Noriko Kinoshita-Iwamoto Tomiteru Togano Akira Hangaishi Katsuyuki Shiratori Yuki Takamatsu Kenji Maeda Yukihito Ishizaka Hiroshi Ohtsu Masahiro Satake Hiroaki Mitsuya Norio Ohmagari |
| author_facet | Mari Terada Sho Saito Satoshi Kutsuna Noriko Kinoshita-Iwamoto Tomiteru Togano Akira Hangaishi Katsuyuki Shiratori Yuki Takamatsu Kenji Maeda Yukihito Ishizaka Hiroshi Ohtsu Masahiro Satake Hiroaki Mitsuya Norio Ohmagari |
| author_sort | Mari Terada |
| collection | DOAJ |
| description | Convalescent plasma therapy, which involves administering plasma from recovered coronavirus disease 2019 (COVID-19) patients to infected individuals, is being explored as a potential treatment for severe cases of COVID-19. This study aims to evaluate the efficacy and safety of convalescent plasma therapy in COVID-19 patients with moderate to severe illness. An open-label, single-arm intervention study was conducted without a control group. Plasma collected from recovered COVID-19 patients was administered to eligible participants. The primary endpoint was the proportion of patients who were placed on artificial ventilation or died within 14 days of transfusion. Secondary endpoints included clinical improvement, viral load measurements, and adverse event monitoring. A total of 59 cases were included in the study. The primary endpoint was evaluated by comparing the rate obtained in the study to an existing rate of 25%. The study also assessed clinical improvement, viral load changes, and safety endpoints through adverse event monitoring. Convalescent plasma therapy shows potential as a treatment option for COVID-19. This study aimed to provide evidence for the efficacy and safety of this therapy and may contribute to its future use in treating severe cases of COVID-19. |
| first_indexed | 2024-03-09T16:40:04Z |
| format | Article |
| id | doaj.art-5de9ee3505a147a39aceb2462fd3b1ad |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T16:40:04Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-5de9ee3505a147a39aceb2462fd3b1ad2023-11-24T14:52:30ZengMDPI AGLife2075-17292023-11-011311218410.3390/life13112184Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered IndividualsMari Terada0Sho Saito1Satoshi Kutsuna2Noriko Kinoshita-Iwamoto3Tomiteru Togano4Akira Hangaishi5Katsuyuki Shiratori6Yuki Takamatsu7Kenji Maeda8Yukihito Ishizaka9Hiroshi Ohtsu10Masahiro Satake11Hiroaki Mitsuya12Norio Ohmagari13Center for Clinical Sciences, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo 162-8655, JapanDisease Control and Prevention Center, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo 162-8655, JapanDisease Control and Prevention Center, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo 162-8655, JapanDisease Control and Prevention Center, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo 162-8655, JapanDepartment of Hematology, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo 162-8655, JapanDepartment of Hematology, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo 162-8655, JapanLaboratory Testing Department, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo 162-8655, JapanDepartment of Refractory Viral Infections, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo 162-8655, JapanDivision of Antiviral Therapy Joint Research Center for Human Retrovirus Infection, Kagoshima University, Sakuragaoka, Kagoshima 890-8544, JapanDepartment of Intractable Diseases, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo 162-8655, JapanFaculty of Health Data Science, Juntendo, Hongo, Bunkyo-ku, Tokyo 113-0033, JapanCentral Blood Institute, Japanese Red Cross, Tatsumi, Koto-ku, Tokyo 135-8521, JapanDepartment of Intractable Diseases, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo 162-8655, JapanDisease Control and Prevention Center, National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo 162-8655, JapanConvalescent plasma therapy, which involves administering plasma from recovered coronavirus disease 2019 (COVID-19) patients to infected individuals, is being explored as a potential treatment for severe cases of COVID-19. This study aims to evaluate the efficacy and safety of convalescent plasma therapy in COVID-19 patients with moderate to severe illness. An open-label, single-arm intervention study was conducted without a control group. Plasma collected from recovered COVID-19 patients was administered to eligible participants. The primary endpoint was the proportion of patients who were placed on artificial ventilation or died within 14 days of transfusion. Secondary endpoints included clinical improvement, viral load measurements, and adverse event monitoring. A total of 59 cases were included in the study. The primary endpoint was evaluated by comparing the rate obtained in the study to an existing rate of 25%. The study also assessed clinical improvement, viral load changes, and safety endpoints through adverse event monitoring. Convalescent plasma therapy shows potential as a treatment option for COVID-19. This study aimed to provide evidence for the efficacy and safety of this therapy and may contribute to its future use in treating severe cases of COVID-19.https://www.mdpi.com/2075-1729/13/11/2184COVID-19SARS-CoV-2convalescent plasmaantiviral therapyemerging infectious diseasesneutralizing antibodies |
| spellingShingle | Mari Terada Sho Saito Satoshi Kutsuna Noriko Kinoshita-Iwamoto Tomiteru Togano Akira Hangaishi Katsuyuki Shiratori Yuki Takamatsu Kenji Maeda Yukihito Ishizaka Hiroshi Ohtsu Masahiro Satake Hiroaki Mitsuya Norio Ohmagari Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals Life COVID-19 SARS-CoV-2 convalescent plasma antiviral therapy emerging infectious diseases neutralizing antibodies |
| title | Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals |
| title_full | Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals |
| title_fullStr | Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals |
| title_full_unstemmed | Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals |
| title_short | Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals |
| title_sort | efficacy and safety of treatment with plasma from covid 19 recovered individuals |
| topic | COVID-19 SARS-CoV-2 convalescent plasma antiviral therapy emerging infectious diseases neutralizing antibodies |
| url | https://www.mdpi.com/2075-1729/13/11/2184 |
| work_keys_str_mv | AT mariterada efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT shosaito efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT satoshikutsuna efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT norikokinoshitaiwamoto efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT tomiterutogano efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT akirahangaishi efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT katsuyukishiratori efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT yukitakamatsu efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT kenjimaeda efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT yukihitoishizaka efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT hiroshiohtsu efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT masahirosatake efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT hiroakimitsuya efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals AT norioohmagari efficacyandsafetyoftreatmentwithplasmafromcovid19recoveredindividuals |